Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics : BofA Securities Starts 4D Molecular Therapeutics at Buy With $47 Price Target

01/05/2021 | 08:30am EST


ę MT Newswires 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
01/14BofA Securities Says IPO Performance Was Weak in 2021 But Fundamentals Remain Intact fo..
MT
01/114D MOLECULAR THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
01/104D Molecular Therapeutics' Treatment for Retinal Disorder Gets FDA Fast Track Designati..
MT
01/104D Molecular Therapeutics Gets Fast-Track Designation for Retinal Disease Treatment
DJ
01/104D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for th..
AQ
01/104D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for th..
CI
01/064D Molecular Says First Patient Dosed in Trial of 4D-150 Candidate to Treat Eye Disease
MT
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
GL
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
GL
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 18,8 M - -
Net income 2021 -71,7 M - -
Net cash 2021 318 M - -
P/E ratio 2021 -5,56x
Yield 2021 -
Capitalization 459 M 459 M -
EV / Sales 2021 7,50x
EV / Sales 2022 43,7x
Nbr of Employees 121
Free-Float -
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 14,28 $
Average target price 45,25 $
Spread / Average Target 217%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-34.91%459
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508